Evidence map›Paper›PMID 36173505›Full record

ArticleInflammopharmacology2022

Angiotensin type 2 receptor antagonism as a new target to manage gout.

Thiago Neves Vieira, André L Lopes Saraiva, Rafaela Mano Guimarães, João Paulo Mesquita Luiz, Larissa Garcia Pinto, Veridiana de Melo Rodrigues Ávila, Luiz Ricardo Goulart, Jair Pereira Cunha-Junior, Peter Anthony McNaughton, Thiago Mattar Cunha and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Inflammopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Thiago Neves VieiraGraduate Program in Genetics and Biochemistry, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia, MG, 38408-100, Brazil.
André L Lopes SaraivaGraduate Program in Genetics and Biochemistry, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia, MG, 38408-100, Brazil.
Rafaela Mano GuimarãesCenter for Research in Inflammatory Diseases (CRID), Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
João Paulo Mesquita LuizCenter for Research in Inflammatory Diseases (CRID), Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
Larissa Garcia PintoWolfson Centre for Age-Related Diseases, King's College London, Guy's Campus, London, SE1 1UL, UK.
Veridiana de Melo Rodrigues ÁvilaGraduate Program in Genetics and Biochemistry, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia, MG, 38408-100, Brazil.
Luiz Ricardo Goulart *Graduate Program in Genetics and Biochemistry, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia, MG, 38408-100, Brazil.
Jair Pereira Cunha-JuniorDepartment of Immunology, Institute of Sciences Biomedical Sciences, Federal University of Uberlândia, Uberlândia, MG, 38405-318, Brazil.
Peter Anthony McNaughtonWolfson Centre for Age-Related Diseases, King's College London, Guy's Campus, London, SE1 1UL, UK.
Thiago Mattar CunhaCenter for Research in Inflammatory Diseases (CRID), Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
Juliano FerreiraGraduated Program in Pharmacology, Pharmacology Department, Federal University of Santa Catarina (UFSC), Florianopolis, SC, 88049-900, Brazil.
Cassia Regina SilvaGraduate Program in Genetics and Biochemistry, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia, MG, 38408-100, Brazil. cassia.regina@ufu.br.ORCID http://orcid.org/0000-0002-1353-2570
Universidade Federal de Uberlândia · BRUniversidade de São Paulo · BRKing's College London · GBUniversidade Federal de Santa Catarina · BR

Funding

Medical Research Council MR/J013129/1Medical Research Council MR/J013129/2Wellcome Trust 205006Wellcome Trust 205006/Z/16/Z
6 · The paper itself

Abstract

backgroundThere is a growing search for therapeutic targets in the treatment of gout. The present study aimed to evaluate the analgesic and anti-inflammatory potential of angiotensin type 2 receptor (AT

methodsMale wild-type (WT) C57BL/6 mice either with the AT

resultsAT

conclusionOur findings show that AT

Indexed as

Acute PainArthritis, GoutyGoutAngiotensin IIAngiotensin II Type 2 Receptor BlockersAnimalsAnti-Inflammatory AgentsAntioxidantsEdemaHyperalgesiaMaleMiceMice, Inbred C57BLPeroxidaseReceptor, Angiotensin, Type 2RNA, MessengerAngiotensin IIAngiotensin II Type 2 Receptor BlockersAnti-Inflammatory AgentsAntioxidantsPeroxidaseReceptor, Angiotensin, Type 2RNA, MessengerUric AcidArthritisIL-1βInflammationMonosodium urate crystalsPain

Identifiers

PMID36173505
PMCPMC7614762
OpenAlexW4297536008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.